Butterfly Network, Inc. (BFLY) Bundle
An Overview of Butterfly Network, Inc. (BFLY)
General Summary of Butterfly Network, Inc. (BFLY)
Butterfly Network, Inc. (BFLY) is a pioneering medical technology company founded in 2014, specializing in advanced ultrasound imaging solutions. The company is known for its innovative handheld ultrasound device, the Butterfly iQ, which utilizes a single, portable probe to provide high-quality imaging. This technology aims to improve access to medical imaging and enhance diagnostic capabilities in various healthcare settings.
As of 2024, Butterfly Network has expanded its product offerings to include the iQ3 probe, which features enhanced capabilities and higher selling prices, contributing significantly to its revenue. In 2024, the company reported total sales of approximately $59.7 million, up from $49.4 million in the previous year, marking a growth of 20.9% year-over-year.
Year | Total Sales (in millions) | Product Revenue (in millions) | Software Revenue (in millions) |
---|---|---|---|
2024 | $59.7 | $39.5 | $20.2 |
2023 | $49.4 | $29.9 | $19.5 |
Company's Financial Performance in the Latest Financial Reports
In the latest financial reports for the third quarter of 2024, Butterfly Network demonstrated a record-breaking revenue performance. For the three months ended September 30, 2024, the company generated total revenue of $20.6 million, a 33.3% increase from $15.4 million in the same period of 2023. This growth was primarily driven by a substantial increase in product sales, particularly from the iQ3 probe.
Product revenue for the third quarter of 2024 was reported at $13.5 million, up 54.7% compared to $8.8 million in the prior year. Software and other services revenue also saw a modest increase of 5.3%, bringing in $7.0 million. The gross profit for the quarter was $12.2 million, resulting in a gross margin of 59.3%.
Despite the revenue growth, the company reported a net loss of $16.9 million for the third quarter, although this was an improvement from a loss of $27.4 million in the same quarter of 2023. The decrease in net loss was attributed to reduced operating expenses and improved revenue performance.
Financial Metrics | Q3 2024 | Q3 2023 | Change (%) |
---|---|---|---|
Total Revenue | $20.6 million | $15.4 million | 33.3% |
Product Revenue | $13.5 million | $8.8 million | 54.7% |
Net Loss | ($16.9 million) | ($27.4 million) | 38.4% |
Introduction to Company as a Leader in the Industry
Butterfly Network, Inc. has established itself as a leader in the medical imaging industry, particularly in the ultrasound segment. The company’s innovative approach to diagnostic imaging, characterized by its handheld and easy-to-use devices, has transformed how healthcare providers access ultrasound technology. As of 2024, Butterfly Network continues to expand its market presence and product offerings, focusing on enhancing the capabilities of its ultrasound devices and software solutions.
With a commitment to improving patient outcomes and making medical imaging more accessible, Butterfly Network is well-positioned for future growth. Investors and stakeholders are encouraged to explore further how the company's unique value proposition and technological advancements contribute to its success in the healthcare sector.
Mission Statement of Butterfly Network, Inc. (BFLY)
Mission Statement Overview
Butterfly Network, Inc. (BFLY) emphasizes the significance of its mission statement in guiding its long-term goals. The mission statement serves as a foundational element that shapes the company's strategic direction, operational priorities, and commitment to stakeholders.
Core Component 1: Innovation
Butterfly Network's mission is rooted in innovation, aiming to revolutionize medical imaging by providing accessible, affordable, and high-quality ultrasound solutions. The company has developed the Butterfly iQ device, a handheld ultrasound that integrates advanced imaging technology with a user-friendly application. As of September 30, 2024, Butterfly Network reported a product revenue increase of $4.8 million, or 54.7%, compared to the same period in the previous year, showcasing the impact of its innovative offerings.
Core Component 2: Accessibility
The second core component is accessibility. Butterfly Network is dedicated to democratizing healthcare by making ultrasound technology available to a broader range of healthcare providers. The company’s mission underscores its commitment to ensuring that healthcare professionals, regardless of their location, can utilize advanced imaging tools. In 2024, the company launched the iQ3 probe, which has a higher selling price but is designed to enhance accessibility through improved functionality. The increase in international probe sales further supports this commitment, with total product revenue reaching $39.5 million in the nine months ended September 30, 2024.
Core Component 3: Quality
Lastly, the mission statement emphasizes quality in product development and customer service. Butterfly Network is focused on providing high-quality imaging solutions that meet rigorous medical standards. The company’s commitment to quality is reflected in its 43% of revenue spent on research and development as of September 30, 2024, amounting to $8.8 million in R&D expenses. This investment is critical for ongoing product improvements and ensuring that healthcare providers receive reliable and effective tools for patient care.
Financial Metrics | Q3 2024 | Q3 2023 | Change ($) | Change (%) |
---|---|---|---|---|
Product Revenue | $13.5 million | $8.8 million | $4.8 million | 54.7% |
Software and Services Revenue | $7.0 million | $6.7 million | $0.4 million | 5.3% |
R&D Expenses | $8.8 million | $12.1 million | ($3.3 million) | (27.1%) |
Net Loss | ($16.9 million) | ($27.4 million) | $10.5 million | 38.3% |
Vision Statement of Butterfly Network, Inc. (BFLY)
Vision Statement Overview
Butterfly Network, Inc. (BFLY) aims to democratize medical imaging through innovative technology, making high-quality ultrasound accessible to every clinician and patient. The vision emphasizes the integration of advanced technology in healthcare to enable better patient outcomes.
Commitment to Innovation
Butterfly Network is dedicated to continuous innovation in medical imaging technology. The company has significantly invested in research and development, reporting R&D expenses of $28.975 million for the nine months ended September 30, 2024, a decrease of 34.8% compared to $44.409 million for the same period in 2023 . This commitment reflects their vision of advancing ultrasound technology to improve diagnostic capabilities.
Accessibility of Medical Imaging
Butterfly Network's vision includes making ultrasound technology widely accessible. The company reported a 32.1% increase in product revenue, reaching $39.478 million for the nine months ended September 30, 2024, compared to $29.874 million in the same period of 2023 . This growth indicates their success in expanding access to ultrasound technology across various healthcare settings.
Enhancing Patient Outcomes
The company's focus on improving patient outcomes is demonstrated through its strategic initiatives and partnerships. Butterfly Network's software and other services revenue increased by 3.7%, totaling $20.227 million for the nine months ended September 30, 2024, compared to $19.510 million in 2023 . This growth is a testament to the effectiveness of their technology in enhancing clinical decision-making.
Global Reach and Impact
Butterfly Network envisions a global impact through its innovative ultrasound solutions. The company has seen an increase in international probe sales, contributing to its product revenue growth. The increase in revenue from international sales reflects a broader reach in the healthcare market, aligning with their vision to provide accessible imaging solutions worldwide .
Financial Performance Summary
Metric | Q3 2024 | Q3 2023 | Change |
---|---|---|---|
Product Revenue | $13.538 million | $8.753 million | +54.7% |
Software and Other Services Revenue | $7.023 million | $6.668 million | +5.3% |
Total Revenue | $20.561 million | $15.421 million | +33.3% |
Net Loss | $(16.924) million | $(27.368) million | Improvement |
Future Directions
Butterfly Network continues to align its vision with strategic initiatives aimed at expanding its market presence and enhancing its product offerings. The company is focused on leveraging its technological advancements to maintain its leadership position in the medical imaging industry while addressing the needs of healthcare providers and patients alike.
Core Values of Butterfly Network, Inc. (BFLY)
Core Value: Innovation
Butterfly Network, Inc. prioritizes innovation as a core value, driving the development of groundbreaking medical imaging technologies. The launch of the iQ3 probe exemplifies this commitment, offering advanced imaging capabilities that enhance diagnostic accuracy.
In the nine months ended September 30, 2024, product revenue increased by $9.6 million, or 32.1%, compared to the same period in 2023, primarily driven by the iQ3 probe's higher selling price and increased sales internationally .
Core Value: Accessibility
Butterfly Network is dedicated to making medical imaging accessible to a broader audience. This is reflected in their pricing strategies and partnerships with healthcare systems to integrate their devices into various medical practices.
In 2024, the company reported total revenue of $59.7 million for the nine months ended September 30, 2024, compared to $49.4 million in the same period in 2023, showcasing their effort to expand access to their technology .
Core Value: Collaboration
Collaboration is essential for Butterfly Network, as they work closely with healthcare professionals to refine their products and services. This approach ensures that their offerings meet the real-world needs of users.
For the nine months ended September 30, 2024, the company reported a 3.7% increase in software and other services revenue, totaling $20.2 million, which was aided by licensing revenues from partnerships .
Core Value: Integrity
Butterfly Network emphasizes integrity in all its operations, ensuring transparency with stakeholders and adherence to ethical standards in product development.
The company has faced legal challenges, resulting in a decrease in legal costs by $6.8 million in the nine months ended September 30, 2024, reflecting their commitment to managing legal matters effectively .
Core Value: Excellence
Excellence is a guiding principle at Butterfly Network, driving them to deliver high-quality products and services consistently.
Despite a net loss of $54.4 million for the nine months ended September 30, 2024, the company continues to invest in research and development, spending $28.98 million during the same period, a decrease from $44.41 million in 2023, indicating a focus on operational efficiency .
Core Value | Description | Recent Initiatives/Results |
---|---|---|
Innovation | Commitment to developing groundbreaking medical imaging technologies. | Product revenue increased by 32.1% due to iQ3 probe sales. |
Accessibility | Making medical imaging technologies available to a broader audience. | Total revenue reached $59.7 million, up from $49.4 million in 2023. |
Collaboration | Working closely with healthcare professionals to refine products. | Software and services revenue increased by 3.7% to $20.2 million. |
Integrity | Ensuring transparency and ethical standards in operations. | Legal costs decreased by $6.8 million in 2024. |
Excellence | Delivering high-quality products and services consistently. | R&D expenses were $28.98 million for the nine months ended September 30, 2024. |
Butterfly Network, Inc. (BFLY) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Article updated on 8 Nov 2024
Resources:
- Butterfly Network, Inc. (BFLY) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Butterfly Network, Inc. (BFLY)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Butterfly Network, Inc. (BFLY)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.